Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crizotinib + dasatinib
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of crizotinib and dasatinib is an investigational drug combination that has been studied in clinical trials for various cancer types. This combination targets multiple signaling pathways involved in cancer progression. It is a combination of crizotinib (a MET inhibitor) and dasatinib (a c-SRC inhibitor) investigated for the treatment of advanced cancers. Preclinical studies demonstrated cross-talk between MET and c-SRC molecules, suggesting potential synergistic effects. However, clinical trials showed limited tolerability due to high rates of adverse events and modest efficacy.
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on crizotinib + dasatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crizotinib + dasatinib.